GSK plc (LON:GSK)
2,250.00
+28.77 (1.30%)
At close: Feb 18, 2026
GSK plc Revenue
In the year 2025, GSK plc had annual revenue of 32.67B GBP with 4.11% growth. GSK plc had revenue of 8.62B in the quarter ending December 31, 2025, with 6.17% growth.
Revenue
32.67B
Revenue Growth
+4.11%
P/S Ratio
2.62
Revenue / Employee
475.99K
Employees
68,629
Market Cap
85.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.67B | 1.29B | 4.11% |
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
| Dec 31, 2018 | 30.82B | 635.00M | 2.10% |
| Dec 31, 2017 | 30.19B | 2.30B | 8.24% |
| Dec 31, 2016 | 27.89B | 3.97B | 16.58% |
| Dec 31, 2015 | 23.92B | 917.00M | 3.99% |
| Dec 31, 2014 | 23.01B | -3.50B | -13.20% |
| Dec 31, 2013 | 26.51B | 74.00M | 0.28% |
| Dec 31, 2012 | 26.43B | -956.00M | -3.49% |
| Dec 31, 2011 | 27.39B | -1.01B | -3.54% |
| Dec 31, 2010 | 28.39B | 24.00M | 0.08% |
| Dec 31, 2009 | 28.37B | 4.02B | 16.49% |
| Dec 31, 2008 | 24.35B | 1.64B | 7.20% |
| Dec 31, 2007 | 22.72B | -509.00M | -2.19% |
| Dec 31, 2006 | 23.23B | 1.57B | 7.23% |
| Dec 31, 2005 | 21.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| CVS Group | 673.20M |
| Genus | 672.80M |
GSK plc News
- 6 hours ago - Ex-Dividend Reminder: Shell, Patria Investments and Glaxosmithkline - Nasdaq
- 8 hours ago - GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows - Business Wire
- 1 day ago - GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade) - Seeking Alpha
- 1 day ago - GSK's Arexvy Vaccine Shows Strong Effectiveness in Real-World Study - GuruFocus
- 1 day ago - GSK says RSV shot Arexvy lowers risk of CV events, asthma, and COPD - Seeking Alpha
- 1 day ago - GSK wins approval of Exdensur in Europe for severe asthma - Seeking Alpha
- 1 day ago - GSK Reports Promising Data for RSV Vaccine Effectiveness - GuruFocus
- 1 day ago - Europe Clears GSK's New Twice-Yearly Asthma Treatment - Benzinga